" class="no-js "lang="en-US"> Kathrin Jansen - Medtech Alert
Tuesday, June 18, 2024
Kathrin Jansen

Kathrin Jansen

About Kathrin Jansen

A member of Pfizer’s Worldwide Research, Development, and Medical leadership team, Dr. Jansen leads a fully integrated, global vaccines research and development organization. Her responsibilities range from discovery to registration and post-marketing commitments and a clinical vaccines portfolio that includes vaccines to prevent or treat diseases of significant unmet medical need. These include Streptococcus pneumonia, Clostridium difficile, Respiratory syncytial virus, Group B streptococcus and prostate cancer. Dr. Jansen’s recent accomplishments are the global licensures of Prev(e)nar13® to prevent pneumococcal diseases and the development and licensure of Trumenba®, the first vaccine licensed in the United States to prevent invasive disease caused by Neisseria meningitidis serogroup B.

While at Merck Research Laboratories, Dr. Jansen initiated R&D activities and led the development of Gardasil®, the world’s first cervical cancer vaccine. She has authored and co-authored over 170 publications, and is member of the Coalition for Epidemic Preparedness Innovations (CEPI) scientific advisory committee, American Society for Microbiology and a Fellow of the Royal Society of Medicine. Dr. Jansen has over 25 years of pharmaceutical experience in vaccine research and development.

Related Story

Valneva and Pfizer Enter Into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15

June 20 2022

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced […]

Pfizer Starts Study of mRNA-based Next Generation Flu Vaccine Program

September 28 2021

Pfizer Inc. (NYSE: PFE) announced today that the first participants have been dosed in a Phase […]

Pfizer Announces Start of Phase 3 Clinical Trial in Adults for its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)

September 3 2021

Pfizer Inc. (NYSE:PFE) today announced the initiation of RENOIR (RSV vaccine Efficacy study iNOlder adults Immunized against RSV […]

U.S. FDA Approves Prevnar 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older

June 9 2021

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved […]